Savara to Participate in Two Upcoming Investor Healthcare Conferences

Rhea-AI Summary

Savara Inc. (NASDAQ: SVRA) announced its participation in two upcoming healthcare conferences. A pre-recorded presentation for the H.C. Wainwright 23rd Annual Global Investment Conference will be available from 7:00 AM ET on September 13, 2021. Additionally, a live presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is scheduled for 12:25 PM ET on September 20, 2021. Both presentations will be accessible on Savara's Investors page for 90 days.

H.C. Wainwright 23rd Annual Global Investment Conference

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare conferences:

• H.C. Wainwright 23rd Annual Global Investment Conference: A pre-recorded webcast of the presentation will be available beginning at 7:00 AM ET / 4:00 AM PT on September 13, 2021.
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: A live webcast of the presentation will take place at 12:25 PM ET / 9:25 AM PT on September 20, 2021.

Both webcast presentations will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow^® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

More information can be found at https://savarapharma.com/. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005242/en/

Savara Inc. IR & PR

Anne Erickson (anne.erickson@savarapharma.com)

(512) 851-1366

Source: Savara Inc.

FAQ

What are the dates for Savara Inc.'s presentations at the healthcare conferences in September 2021?

Savara Inc. will present at the H.C. Wainwright conference on September 13, 2021, and at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021.

Where can I watch the presentations from Savara Inc.?

The presentations can be accessed on Savara's Investors page at www.savarapharma.com/investors/events-presentations/.

What is the focus of Savara Inc.'s clinical programs?

Savara Inc. focuses on developing treatments for rare respiratory diseases, with its lead program being molgramostim for autoimmune pulmonary alveolar proteinosis.

What time will the live presentation from Savara Inc. occur on September 20, 2021?

The live presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place at 12:25 PM ET on September 20, 2021.